We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

48 hedge funds and large institutions have $123M invested in NKGen Biotech, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

12% more funds holding

Funds holding: 43 → 48 (+5)

6% more capital invested

Capital invested by funds: $117M → $123M (+$6.72M)

Holders
48
Holders Change
+5
Holders Change %
+11.63%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$3.43M
2
CSS
Cubist Systematic Strategies
Connecticut
+$3.23M
3
CF
Cantor Fitzgerald
New York
+$2.48M
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$1.6M
5
EAM
Exos Asset Management
New York
+$700K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$3.39M
2
SG
StoneX Group
New York
-$97K
3
HighTower Advisors
HighTower Advisors
Illinois
-$3.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$13.1M – – –
HCM
2
Highbridge Capital Management
New York
$10.9M – – –
RCM
3
Radcliffe Capital Management
Pennsylvania
$5.85M – – –
PC
4
Periscope Capital
Ontario, Canada
$5.82M – – –
KC
5
Kepos Capital
New York
$5.1M – – –
CSS
6
Cubist Systematic Strategies
Connecticut
$4.86M +$3.23M +332,492 +198%
6CM
7
683 Capital Management
New York
$4.86M – – –
FTCM
8
Fir Tree Capital Management
New York
$4.86M – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
9
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$4.86M – – –
KL
10
KIM LLC
Kansas
$4.47M +$4.48M +460,200 New
SCM
11
Saba Capital Management
New York
$4.03M – – –
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$3.88M – – –
PSAMP
13
P. Schoenfeld Asset Management (PSAM)
New York
$3.88M – – –
Goldman Sachs
14
Goldman Sachs
New York
$3.54M – – –
UOC
15
UBS O'Connor
Illinois
$3.42M +$3.43M +352,688 New
TCA
16
Taconic Capital Advisors
New York
$3.4M – – –
FBCM
17
Fort Baker Capital Management
California
$2.93M – – –
PAMP
18
Polar Asset Management Partners
Ontario, Canada
$2.91M – – –
CL
19
CSS LLC
Illinois
$2.83M +$5.09K +523 +0.2%
CF
20
Cantor Fitzgerald
New York
$2.48M +$2.48M +255,000 New
SCM
21
Shaolin Capital Management
Florida
$2.46M – – –
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$2.45M – – –
Millennium Management
23
Millennium Management
New York
$2.37M – – –
AIMCA
24
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.94M – – –
RCM
25
Rivernorth Capital Management
Florida
$1.91M – – –
1
2 3

NKGN Hedge Fund Activity: Q2 2022 in Review

48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2022, worth a combined $123M — up 5.8% from $117M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $3.43M. The largest seller was Bank of America, exiting entirely with an estimated $3.39M sold.

  • 48 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2022, up from 43 in Q1 2022.
  • Funds reported $123M of NKGen Biotech, Inc. Common Stock stock for Q2 2022, up 5.8% quarter-over-quarter.
  • 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of +6 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2022 was UBS O'Connor, an estimated $3.43M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q2 2022 was Bank of America, an estimated $3.39M sold.

Based on aggregated 13F filings for Q2 2022.